ARS Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
SPRY$3.57+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common · Other · Total | ||||||
| Stock · Additional · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Paid-in Capital | Gain (Loss), Net | Deficit | Equity | |
| Balance at December 31, 2024 | 97,954,172 | $10 | $379,873 | $220 | $(123,305) | $256,798 |
| Exercise of common stock options and release of restricted stock units | 175,632 | — | 725 | — | — | 725 |
| Stock-based compensation | — | — | 5,539 | — | — | 5,539 |
| Net loss and comprehensive loss | — | — | — | (148) | (33,940) | (34,088) |
| Balance at March 31, 2025 | 98,129,804 | 10 | 386,137 | 72 | (157,245) | 228,974 |
| Exercise of common stock options and issuance of common stock under the employee stock purchase plan | 567,854 | — | 2,697 | — | — | 2,697 |
| Stock-based compensation | — | — | 5,651 | — | — | 5,651 |
| Net loss and comprehensive loss | — | — | — | (118) | (44,883) | (45,001) |
| Balance at June 30, 2025 | 98,697,658 | 10 | 394,485 | (46) | (202,128) | 192,321 |
| Exercise of common stock options | 146,520 | — | 479 | — | — | 479 |
| Stock-based compensation | — | — | 5,967 | — | — | 5,967 |
| Net loss and comprehensive loss | — | — | — | 39 | (51,151) | (51,112) |
| Balance at September 30, 2025 | 98,844,178 | $10 | $400,931 | $(7) | $(253,279) | $147,655 |
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common · Other · Total | ||||||
| Stock · Additional · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Paid-in Capital | Gain (Loss), Net | Deficit | Equity | |
| Balance at December 31, 2023 | 96,414,963 | $10 | $362,004 | $49 | $(131,303) | $230,760 |
| Exercise of common stock options and release of restricted stock units | 159,086 | — | 258 | — | — | 258 |
| Stock-based compensation | — | — | 3,315 | — | — | 3,315 |
| Net loss and comprehensive loss | — | — | — | (173) | (10,292) | (10,465) |
| Balance at March 31, 2024 | 96,574,049 | 10 | 365,577 | (124) | (141,595) | 223,868 |
| Exercise of common stock options, shares issued under the employee stock purchase plan, and release of restricted stock units | 365,748 | — | 545 | — | — | 545 |
| Stock-based compensation | — | — | 3,365 | — | — | 3,365 |
| Net loss and comprehensive loss | — | — | — | (21) | (12,516) | (12,537) |
| Balance at June 30, 2024 | 96,939,797 | 10 | 369,487 | (145) | (154,111) | 215,241 |
| Exercise of common stock options and release of restricted stock units | 207,645 | — | 680 | — | — | 680 |
| Stock-based compensation | — | — | 3,701 | — | — | 3,701 |
| Net loss and comprehensive loss | — | — | — | 484 | (19,128) | (18,644) |
| Balance at September 30, 2024 | 97,147,442 | $10 | $373,868 | $339 | $(173,239) | $200,978 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.